Forum Financial Management LP acquired a new stake in shares of Johnson & Johnson (NYSE: JNJ – Get Rating) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 27,586 shares of the company stock, valued at approximately $ 4,719,000. Johnson & Johnson accounts for approximately 0.2% of Forum Financial Management LP’s portfolio, making the stock its 23rd biggest position.
A number of other hedge funds have also bought and sold shares of JNJ. Steward Financial Group LLC purchased a new stake in Johnson & Johnson during the 4th quarter valued at $ 34,000. Iron Horse Wealth Management LLC increased its stake in Johnson & Johnson by 29.9% in the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company stock worth $ 45,000 after purchasing an additional 61 shares during the period. Gibson Wealth Advisors LLC bought a new position in shares of Johnson & Johnson during the 4th quarter worth $ 49,000. Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Johnson & Johnson by 290.7% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company stock worth $ 47,000 after buying an additional 218 shares in the last quarter. Finally, Monolith Advisors bought a new position in shares of Johnson & Johnson during the 4th quarter worth $ 69,000. Institutional investors and hedge funds own 68.78% of the company stock.
A number of brokerages recently weighed in on JNJ. Credit Suisse Group raised their price target on Johnson & Johnson from $ 200.00 to $ 205.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Citigroup reduced their price objective on Johnson & Johnson from $ 210.00 to $ 205.00 in a research note on Tuesday, May 17th. Morgan Stanley reduced their price target on Johnson & Johnson from $ 175.00 to $ 173.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 6th. Sanford C. Bernstein cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and lifted their price target for the company from $ 180.00 to $ 183.00 in a research report on Wednesday, March 16th. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $ 190.50.
Shares of NYSE: JNJ opened at $ 169.99 on Thursday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. The business’s 50 day moving average price is $ 178.59 and its 200-day moving average price is $ 172.62. The firm has a market capitalization of $ 447.31 billion, a PE ratio of 22.91, a P / E / G ratio of 3.41 and a beta of 0.66. Johnson & Johnson has a 1 year low of $ 155.72 and a 1 year high of $ 186.69.
Johnson & Johnson (NYSE: JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, April 19th. The company reported $ 2.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $ 2.60 by $ 0.07. The firm had revenue of $ 23.43 billion for the quarter, compared to analyst estimates of $ 23.62 billion. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The business’s revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the company posted $ 2.59 earnings per share. As a group, analysts expect that Johnson & Johnson will post 10.23 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th were paid a $ 1.13 dividend. The ex-dividend date of this dividend was Monday, May 23rd. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $ 1.06. This represents a $ 4.52 dividend on an annualized basis and a dividend yield of 2.66%. Johnson & Johnson’s payout ratio is currently 60.92%.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction on Friday, June 10th. The stock was sold at an average price of $ 173.00, for a total transaction of $ 6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares of the company stock, valued at $ 12,336,803. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider William Hait sold 29,699 shares of the business’s stock in a transaction on Thursday, April 21st. The stock was sold at an average price of $ 183.58, for a total value of $ 5,452,142.42. Following the transaction, the insider now directly owns 80,236 shares in the company, valued at approximately $ 14,729,724.88. The disclosure for this sale can be found here. Insiders sold 78,161 shares of company stock worth $ 13,895,302 over the last ninety days. Corporate insiders own 0.35% of the company stock.
Johnson & Johnson Profile: (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health / beauty products under the AVEENO, CLEAN & CLEAR, DR.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE: JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.